Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset

被引:13
|
作者
Lieber, Sarah B. [1 ,2 ]
Navarro-Millan, Iris [1 ,2 ]
Rajan, Mangala [2 ]
Curtis, Jeffrey R. [3 ]
Sattui, Sebastian E. [4 ]
Lui, Geyanne [5 ]
Schwartzman, Sergio [1 ,2 ]
Mandl, Lisa A. [1 ,2 ]
机构
[1] Hosp Special Surg, New York, NY USA
[2] Weill Cornell Med, New York, NY USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] New York Inst Technol, Coll Osteopath Med, Old Westbury, NY 11568 USA
基金
美国国家卫生研究院;
关键词
WOMENS HEALTH; VALIDATION; ADULTS; INDEX;
D O I
10.1002/acr2.11388
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Frailty is associated with disability and mortality independent of age. Although studies have evaluated frailty in rheumatoid arthritis (RA), information on the prevalence of frailty in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) is limited. We aimed to determine the prevalence of frailty in AS and PsA and to evaluate whether characteristics known to be associated with frailty, including anxiety, differ among these three types of inflammatory arthritis. Methods We performed a cross sectional study of Centers for Medicare & Medicaid Services (CMS) beneficiaries aged 65 years or older with AS, PsA, or RA enrolled in 2014. We operationalized frailty using a validated claims-based frailty index. We also explored the prevalence of frailty among CMS beneficiaries younger than age 65 years with work disability, a younger population that also may be at risk of frailty. Results The prevalence of frailty in beneficiaries aged 65 years or older with AS and PsA was 45.2% and 46.7%, respectively, significantly lower than in RA (65.9%, P < 0.05). The prevalence of frailty in beneficiaries less than 65 years old was much lower overall, though still highest in RA; 11.7%, 4.4%, and 7.0% in RA, AS, and PsA, respectively (P < 0.05). Anxiety was significantly associated with frailty in subjects of all ages, particularly among those less than 65 years old (P < 0.05). Conclusion Almost half of beneficiaries with AS or PsA aged 65 years old or older were frail, higher than in younger disabled beneficiaries. Further studies are needed to understand the risks of developing frailty in these diseases. Frailty was associated with anxiety, particularly in the younger age groups.
引用
收藏
页码:300 / 305
页数:6
相关论文
共 50 条
  • [21] THREE TNF-A-INHIBITORS FOR TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
    Ivakhnenko, O.
    Rebrova, O.
    Avxentyeva, M.
    Khachatryan, G.
    VALUE IN HEALTH, 2013, 16 (07) : A564 - A564
  • [22] Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Rubbert-Roth, Andrea
    Kakehasi, Adriana
    Takeuchi, Tsutomu
    Schmalzing, Marc
    Palac, Hannah
    Liu, Jianzhong
    Anyanwu, Samuel
    Lippe, Ralph
    Curtis, Jeffrey
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 562 - 564
  • [23] PATIENT CHARACTERISTICS AND GOLIMUMAB UTILIZATION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS PATIENTS
    Tandon, N.
    Haas, S.
    Bolge, S.
    Gunnarsson, C.
    VALUE IN HEALTH, 2012, 15 (04) : A48 - A48
  • [24] DIFFERENCES IN PROINFLAMMATORY AND LIPID PROFILE BETWEEN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS
    Bonek, K.
    Kuca-Warnawin, E.
    Ciechomska, M.
    Gluszko, P.
    Kontny, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 822 - 822
  • [25] The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
    Furst, Daniel E.
    Kay, Jonathan
    Wasko, Mary Chester
    Keystone, Edward
    Kavanaugh, Arthur
    Deodhar, Atul
    Murphy, Frederick T.
    Magnus, Jeanette H.
    Hsia, Elizabeth C.
    Hsu, Benjamin
    Xu, Stephen
    Rahman, Mahboob U.
    Doyle, Mittie K.
    RHEUMATOLOGY, 2013, 52 (10) : 1845 - 1855
  • [26] EFFECT OF TOFACITINIB ON REDUCING PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Ogdie, A.
    de Vlam, K.
    McInnes, I. B.
    Mease, P. J.
    Baer, P.
    Lukic, T.
    Kwok, K.
    Wang, C.
    Hsu, M. -A.
    Maniccia, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 971 - 972
  • [27] DURATION OF SYMPTOMS BEFORE DIAGNOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Sorensen, J.
    Hetland, M. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 80 - 81
  • [28] Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis
    Zink, A
    Thiele, K
    Huscher, D
    Listing, J
    Sieper, J
    Krause, A
    Gromnica-Ihle, E
    von Hinueber, U
    Wassenberg, S
    Genth, E
    Schneider, M
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 86 - 90
  • [29] Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    Ogdie, Alexis
    de Vlam, Kurt
    McInnes, Iain B.
    Mease, Philip J.
    Baer, Philip
    Lukic, Tatjana
    Kwok, Kenneth
    Wang, Cunshan
    Hsu, Ming-Ann
    Maniccia, Anna
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [30] ANALYSIS OF CHANGES AND SUSPENSION IN BIOLOGICAL TREATMENTS FOR RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
    Maria Inmaculada, Segui Gregori
    Donat Mercedes, Franco
    Milla Amparo, Rocher
    Cortes Jose, Ivorra
    Juan Antonio, Castellano Cuesta
    Company Enrique, Soler
    ATENCION FARMACEUTICA, 2011, 13 (04): : 199 - +